Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1520-1532

  Gomez, O ^a   Sanchez Rodriguez, A ^a   Le, M Q U ^a   Sanchez Caro, C ^a   Molina Holgado, F ^b   Molina Holgado, E ^a  

^a HOSPITAL NACIONAL DE PARAPLÉJICOS   (Spain)

^b UNIVERSITY OF ROEHAMPTON   (United Kingdom)

Author keywords

ACEA; HU210; JWH133; MBP; mTOR; oligodendrocyte progenitor; PI3K Akt

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 MORPHOLINO 8 PHENYLCHROMONE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANTIGEN; CANNABINOID RECEPTOR AGONIST; DEXANABINOL; MAMMALIAN TARGET OF RAPAMYCIN; MYELIN BASIC PROTEIN; N (2 CHLOROETHYL)EICOSATETRAENAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MATURATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NEWBORN; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; CELL DIFFERENTIATION; CELLS, CULTURED; CHROMONES; ENZYME ACTIVATORS; INDOLES; MORPHOLINES; MYELIN PROTEINS; OLIGODENDROGLIA; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; SIROLIMUS; STEM CELLS; TETRAHYDROCANNABINOL; TOR SERINE-THREONINE KINASES;

EID: 84999905115     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01414.x     Document Type: Article

References (44)

1. Aguado T, Palazuelos J, Monory K, Stella N, Cravatt B, Lutz B, et al,. (2006). The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci 26: 1551-1561. (Pubitemid 43237025)
2. Alexander SP, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
3. Arevalo-Martin A, Garcia-Ovejero D, Rubio-Araiz A, Gomez O, Molina-Holgado F, Molina-Holgado E, (2007). Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post-natal rats through cannabinoid receptor 1 and cannabinoid receptor 2. Eur J Neurosci 26: 1548-1559. (Pubitemid 47416530)
4. Barres BA, Hart IK, Coles HS, Burne JF, Voyvodic JT, Richardson WD, et al,. (1992). Cell death and control of cell survival in the oligodendrocyte lineage. Cell 70: 31-46.
5. Berrendero F, Garcia-Gil L, Hernandez ML, Romero J, Cebeira M, de Miguel R, et al,. (1998). Localization of mRNA expression and activation of signal transduction mechanisms for cannabinoid receptor in rat brain during fetal development. Development 125: 3179-3188. (Pubitemid 28434416)
6. Bibollet-Bahena O, Almazan G, (2009). IGF-I-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways. J Neurochem 109: 1440-1451.
7. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al,. (2003). Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signalling in the brain. J Cell Biol 163: 463-468. (Pubitemid 37429860)
8. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, et al,. (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312: 637-641. (Pubitemid 26002235)
9. Cabral GA, Griffin-Thomas L, (2008). Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr Metab Immune Disord Drug Targets 8: 159-172.
10. Cohen SR, Guarnieri M, (1976). Immunochemical measurement of myelin basic protein in developing rat brain: an index of myelin synthesis. Dev Biol 49: 294-299.
11. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al,. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949. (Pubitemid 23026736)
12. Fernández-Ruiz J, Berrendero F, Hernández ML, Ramos JA, (2000). The endogenous cannabinoid system and brain development. Trends Neurosci 23: 14-20. (Pubitemid 30100308)
13. Fernandez-Ruiz J, García C, Sagredo O, Gõmez-Ruiz M, de Lago E, (2010a). The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14: 387-404.
14. Fernandez-Ruiz J, Hernandez M, Ramos JA, (2010b). Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16: 72-91.
15. Flores AI, Narayanan SP, Morse EN, Shick HE, Yin X, Kidd G, et al,. (2008). Constitutively active Akt induces enhanced myelination in the CNS. J Neurosci 28: 7174-7183.
16. Galve-Roperh I, Rueda D, Gõmez del Pulgar T, Velasco G, Guzmán M, (2002). Mechanism of extracellular signal-regulated kinase activation by the CB (1) cannabinoid receptor. Mol Pharmacol 62: 1385-1392. (Pubitemid 35403833)
17. Gaoni Y, Mechoulam R, (1964). Isolation, structure elucidation and partial synthesis of an active constituent of hashish. J Am Chem Soc 1646-47: 11-20.
18. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T, et al,. (2009). The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis 33: 57-71.
19. Gõmez del Pulgar T, Velasco G, Guzmán M, (2000). The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 347: 369-373. (Pubitemid 30229383)
20. Gomez O, Arevalo-Martin A, Garcia-Ovejero D, Ortega-Gutierrez S, Cisneros JA, Almazan G, et al,. (2010). The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation. Glia 58: 1913-1927.
21. Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ, et al,. (2008). A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci 38: 526-536.
22. Gowran A, Noonan J, Campbell VA, (2010). The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther (in press, doi: 10.1111/j.1755-5949.2010.00195.x).
23. Grundy RI, (2002). The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs 11: 1365-1374. (Pubitemid 35174935)
24. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC, (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
25. Marin-Husstege M, Muggironi M, Liu A, Casaccia-Bonnefil P, (2002). Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J Neurosci 22: 10333-10345. (Pubitemid 35416871)
26. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al,. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302: 84-88. (Pubitemid 37210691)
27. McCarthy KD, de Vellis J, (1980). Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85: 890-902. (Pubitemid 10007455)
28. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al,. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
29. Molina-Holgado E, Molina-Holgado F, (2010). Mending the broken brain: neuroimmune interactions in neurogenesis. J Neurochem 114: 1277-1290.
30. Molina-Holgado E, Vela JM, Arevalo-Martin A, Molina-Holgado F, Almazan G, Borrell J, et al,. (2002). Expression of cannabinoid CB1 receptors in oligodendroglial cells: activation of PI-3KAkt signalling pathway promotes cell survival. J Neurosci 22: 9742-9753.
31. Molina-Holgado F, Rubio-Araiz A, Garcia-Ovejero D, Williams RJ, Moore JD, Arevalo-Martin A, et al,. (2007). CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur J Neurosci 25: 629-634.
32. Narayanan SP, Flores AI, Wang F, Macklin WB, (2009). Akt signals through the mammalian target of rapamycin, mTOR, pathway to regulate central nervous system myelination. J Neurosci 29: 6860-6870.
33. Navé BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR, (1999). Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344: 427-431. (Pubitemid 30011599)
34. Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzman M, Galve-Roperh I, (2006). Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 20: 2405-2407.
35. Pertwee RG, (2005a). The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7: E625-E654.
36. Pertwee RG, (2005b). Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168: 1-51.
37. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al,. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588-631.
38. Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A, (2009). Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci 12: 1152-1158.
39. Romero J, García-Palomero E, Berrendero F, García-Gil L, Hernández ML, Ramos JA, et al,. (1997). Atypical location of cannabinoid receptors in white matter areas during rat brain development. Synapse 26: 317-323. (Pubitemid 27240747)
40. Scotter EL, Abood ME, Glass M, (2010). The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 160: 480-498.
41. Sugiura T, Waku K, (2000). 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids 108: 89-106.
42. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al,. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215: 89-97.
43. Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, Levison SW, (2009). Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci 29: 6367-6378.
44. Wullschleger S, Loewith R, Hall MN, (2006). TOR signaling in growth and metabolism. Cell 124: 471-484. (Pubitemid 43199434)